Blackpool CCG Medicines Optimisation

Blackpool CCG Medicines Optimisation

Medicines play an important part in promoting well-being, preventing ill-health and managing disease. Over 700 million prescription items are dispensed in England each year with a cost approaching £8billion.

Medicines Management can be defined in several ways:

The clinical, cost-effective, safe and secure handling of medicines
A system of processes and behaviours that determines how medicines are used by the NHS and patients
Enabling people to make the best possible use of medicines
Our goal is to achieve the best health outcomes for patients where medicines are involved.

If you have any medicines queries please contact NHS Blackpool CCG’s Medicines Management team on 01253 951306 or email


Click each header to expand its content

Medicines RAG list

Please see the links below for background information on the Red, Amber, Green (RAG) classification in relation to prescribing responsibility and also our RAG list of drugs.

Prescribing position statements

28 Day Prescribing 0.3 MB117
Camouflaging Products 0.2 MB2
Cannabis based medicinal products for pain 0.5 MB118
Clinical Need Low Priority Medicines - General 0.3 MB229
Clinical Need Soluble Analgesics 0.5 MB136
Clinical Need Thickeners Position Statement 0.3 MB90
Commercial sponsorship and joint working with the pharmaceutical industry 0.6 MB88
Denosumab Position Statement 0.3 MB87
E-Cigarettes-Position-Statement-v2.0-FINAL-FOR-LMMG-WEBSITE[1] 0.2 MB132
Edoxaban Position Statement 0.2 MB95
Emollients and Sunscreens 0.2 MB159
Free of Charge (FOC) Medicines schemes 0.3 MB82
Generic Biosimilar Medicines Position Statement 0.2 MB91
Generic Prescribing Guidelines 0.3 MB164
Glucose Monitoring Devices 0.5 MB128
Gluten Free Foodstuffs 0.2 MB103
Health Professionals e-cigarettes briefing 0.2 MB79
Holiday Medication 0.2 MB135
Liothyronine 0.2 MB80
Nutritional Supplements Post Bariatric Surgery 0.3 MB100
Ophthalmology Macular Pathways 1.1 MB89
Oral Nutritional Supplements (ONS) in care and nursing homes 0.2 MB129
Out of Area Prescribing 0.2 MB60
Policy for the Provision of Insulin Pumps for Patients with Diabetes Mellitus 0.3 MB114
Position Statement Sip Feeds 0.4 MB97
Prescribing of multivitamins and phenylalanine-free amino acid substitutes for adults and children with phenylketonuria (PKU) 0.7 MB81
Prescribing Vitamins And Minerals 0.3 MB85
Prophylactic supply of catheters post pelvic organ prolapse 0.2 MB69
Stoma Care Products - deodorants and air fresheners 0.4 MB101
Trans Anal Irrigation Devices 0.2 MB87
Vitamin D Position Statement 0.2 MB4
Zero Risk Schemes 0.3 MB76

Prescribing guidance

Axial-Spondyloarthritis-pathway-Version 37 KB69
Cannabis-based-medication-desk-guide-Nov-2018 December-Edit 0.6 MB96
Chronic Non-cancer Pain Guidelines 0.7 MB78
Colomycin prescribing information sheet Non CF indications. 0.2 MB65
Constipation-Pathway-Version 0.7 MB131
COPD guideline 0.6 MB73
Diabetes - Algorithm for antihyperglycaemic therapy in adults with type II Diabetes 0.6 MB86
Diabetes - BG meters and test strips Type-2-Diabetes 0.5 MB193
Diabetes - Glucagon Like Peptide Contract 0.2 MB101
Diabetes - Home Monitoring of Blood Glucose Levels Guideline 0.2 MB97
Diabetes-self-management-contract 0.5 MB128
Edoxaban Prescribing Tip 68 KB134
Erectile-Dysfunction-Guideline-Version 1.0 MB107
Flash Glucose Monitoring policy - L&SC 0.2 MB38
Gastroenterology-Biologics-Pathway-Version 0.4 MB109
Good-practice-guidelines-for-Gender-Dysphoria 0.6 MB85
Gout-Prescribing-Guidance-Version-1.2-FOR-WEBSITE 0.7 MB151
Guidance for Prescribing Second Generation Long Acting Antipsychotic Injections 0.6 MB41
Headache Management Guideline for Adults 0.7 MB50
Hydroxychloroquine-prescriber-information-sheet-v.1.0-FOR-WEBSITE 0.5 MB76
Insulin Toujeo Information Sheet and Good Practice Guide 0.3 MB26
Interim Gender Dysphoria protocol 0.6 MB65
LMMG-Psoriasis-guideline-FOR-WEBSITE 0.5 MB103
Management-of-Behavioural-and-Psychological-Symptoms-of-Dementia-Primary-Care-Summary-Document 0.2 MB78
Mgt-of-Infection-Primary-Care-Guidance-January-2017 0.7 MB142
Neuropathic Pain Guidance (Version 1.2) 0.9 MB89
NWC-SCN01-Clinical-Practice-Summary-Palliative-Care-Final-version 0.6 MB94
Pathway For The Prevention Of Stroke And Systemic Embolism In Non Valvular Atrial Fibrillation Plus TIA 0.8 MB78
Prescription-Management-of-Stoma-and-Continence-Products-Version-1.1-FINAL-FOR-WEBSITE 0.6 MB108
Primary Care Good Prescribing Guide 0.6 MB143
Primary Care Responsibilities in Prescribing and Monitoring Hormone Therapy 0.3 MB84
Psoriasis LMMG Biologic and High Cost Drug Commissioning Pathway v-1.6[1] 0.4 MB109
Psoriatic-Arthritis-Recommended-Treatment-Pathway-Version 0.3 MB107
RA-High-Cost-Drugs-Pathway-v 0.2 MB101
Restless Legs Syndrome guidelines 0.3 MB57
SIP Feeds 0.1 MB99
Trans male prescribing information sheet 0.2 MB13
Trans-female-gender-dysphoria-prescribing-information-sheet-version-1.1[1] 0.2 MB2
Wound care formulary 8.2 MB141

SHARED CARE: Guidelines and information documents

Where shared care has been agreed between prescribers, this section includes documents to support clinicians in clarifying their responsibilities around prescribing and drug/patient monitoring, where relevant.

DMARDs-Shared-Care-Agreement-V1.1 (docx | 0.1 MB)

For drugs listed in the GP+ scheme below, please refer to the GP+ specification (Standard 10: Shared Care). Since drugs may be added to the list in-year, the list below will be the most up-to-date, rather than those listed in the current 2017/18 GP+ document.

Drugs included in GP+ scheme

Drugs not included in GP+ scheme

Patient Group Directions

A Patient Group Direction (PGD) is a written direction that allows the supply and/or administration of a specified medicine(s), by named authorised health professionals, to a well-defined group of patients requiring treatment for a specific condition. The patient must always fit the defined criteria and organisations must ensure that healthcare professionals supplying and/or administering medicines under a PGD are fully trained, competent individuals who are authorised to do so.

Organisations must be in possession of PGDs that are appropriately signed and fully authorised, unsigned copies are not the legal document and are for information purposes only.

Cumbria and Lancashire CCGs have a collaborative arrangement to produce the PGDs for the national vaccination programme.

Vaccine and immunisation PGDs: The signed copies of these PGDs have been distributed to organisations and GP practices. Each organisation or practice is required to keep the signed copy and ensure all health professionals who will be working under it are authorised and have signed the second page under the managerial content section. The documents at the following link are for information only and are not the legal document:

Patient information leaflets

Primary Care Rebate Schemes

Primary care rebate schemes are contractual arrangements offered by pharmaceutical companies, or third party companies, which offer retrospective financial rebates to the CCG on GP prescribing expenditure for particular branded medicine(s). The availability of a scheme does not influence the inclusion of specific medicines in care pathways or formularies.

Current Primary Care Rebate Schemes in place:

  • Fencino (Fentanyl) – Started 1 October 2018
  • Firmagon (Degarelix) – Started 1 September 2016
  • Januvia (Sitagliptin)  – Started 1 September 2018
  • Lixiana (Edoxaban) – Started 1 October 2018
  • Seretide (Fluticasone / Salmeterol) – Started 1 January 2018
  • Spiolto (Tiotropium + Olodaterol) – Started 1 October 2018
  • Clenil Modulite – Started 1 July 2019
  • Longtec (Oxycodone SR) – Started 1 July 2019
  • Sereflo – Started 1 June 2019
  • Xarelto (Rivaroxaban) – Started 1 July 2019

Last updated on 15 August 2019 at 11:01 by communications and engagement manager